Synthaverse

Historical price data

Synthaverse is a Polish biotech company with a mission to develop and deliver health solutions by combining scientific exploration with proprietary manufacturing expertise. The company has achieved commercial success with a portfolio of approved immunotherapy products, including treatments for bladder cancer and serological conflict, while simultaneously operating a contract manufacturing business unit. Its strategy hinges on leveraging its deep experience in biologics production to both advance its own pipeline and provide services to partners, creating a diversified revenue model. Founded in 2021 as a public entity, it seeks to push medical boundaries by continuously implementing new technologies and collaborating with scientific centers.

Integrated expertise in the development and proprietary GMP manufacturing of complex biologics and immunotherapies, serving as the foundation for both its commercial product portfolio and its contract development and manufacturing (CDMO) services.

Synthaverse competes in mature markets against large pharma (e.g., Merck in BCG) and plasma giants (e.g., Grifols, Takeda in immunoglobulins). Its differentiation lies in proprietary manufacturing processes, an integrated product-and-service model, and a strategic EU location offering potential cost and supply chain advantages.